Preclinical evaluation of a recombinant anti-prostate specific membrane antigen single-chain immunotoxin against prostate cancer

Journal of Immunotherapy

Volumn 33, Issue 3, 2010, Pages 262-271

  Wolf, Philipp ^a   Alt, Karen ^a   Wetterauer, David ^a   Bühler, Patrick ^a   Gierschner, Dorothee ^a   Katzenwadel, Arndt ^a   Wetterauer, Ulrich ^a   Elsässer Beile, Ursula ^a  

^a UNIVERSITY OF FREIBURG   (Germany)

Author keywords

Immunotherapy; Immunotoxin; Prostate cancer; Pseudomonas Exotoxin A; PSMA

Indexed keywords

IMMUNOTOXIN; IMMUNOTOXIN D7 PE40; PROSTATE SPECIFIC MEMBRANE ANTIGEN; SINGLE CHAIN FRAGMENT VARIABLE ANTIBODY; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER INHIBITION; CELL VIABILITY; CONTROLLED STUDY; CYTOTOXICITY; HUMAN; HUMAN CELL; IC 50; LIVER TOXICITY; MALE; MOUSE; NONHUMAN; PHAGE DISPLAY; PRIORITY JOURNAL; PROSTATE CANCER; TUMOR XENOGRAFT;

ADP RIBOSE TRANSFERASES; ANIMALS; ANTIGENS, SURFACE; BACTERIAL TOXINS; CELL LINE; CELL LINE, TUMOR; CELL SURVIVAL; DRUG SCREENING ASSAYS, ANTITUMOR; EXOTOXINS; GLUTAMATE CARBOXYPEPTIDASE II; HUMANS; IMMUNOTOXINS; MALE; MICE; MICE, SCID; PROSTATIC NEOPLASMS; RECOMBINANT PROTEINS; SINGLE-CHAIN ANTIBODIES; TUMOR BURDEN; VIRULENCE FACTORS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 77954918678     PISSN: 15249557     EISSN: None     Source Type: Journal    
DOI: 10.1097/CJI.0b013e3181c5495c     Document Type: Article

References (45)

1. Damber JE, Aus G. Prostate cancer. Lancet. 2008;371:1710-1721.
2. Samson DJ, Seidenfeld J, Schmitt B, et al. Systematic review and meta-analysis of monotherapy compared with combined androgen blockade for patients with advanced prostate carcinoma. Cancer. 2002;95:361-376.
3. Wang X, Yin L, Rao P, et al. Targeted treatment of prostate cancer. J Cell Biochem. 2007;102:571-579.
4. Mesters JR, Barinka C, Li W, et al. Structure of glutamate carboxypeptidase II, a drug target in neuronal damage and prostate cancer. Embo J. 2006;25:1375-1384.
5. Schulke N, Varlamova OA, Donovan GP, et al. The homodimer of prostate-specific membrane antigen is a functional target for cancer therapy. Proc Natl Acad Sci U S A. 2003;100:12590-12595.
6. Ghosh A, Heston WD. Tumor target prostate specific membrane antigen (PSMA) and its regulation in prostate cancer. J Cell Biochem. 2004;91:528-539.
7. Pastan I, Hassan R, FitzGerald DJ, et al. Immunotoxin treatment of cancer. Annu Rev Med. 2007;58:221-237.
8. Adams GP, McCartney JE, Tai MS, et al. Highly specific in vivo tumor targeting by monovalent and divalent forms of 741F8 anti-c-erbB-2 single-chain Fv. Cancer Res. 1993;53:4026-4034.
9. Allen TM. Ligand-targeted therapeutics in anticancer therapy. Nat Rev Cancer. 2002;2:750-763.
10. Wolf P, Elsasser-Beile U. Pseudomonas exotoxin A: from virulence factor to anti-cancer agent. Int J Med Microbiol. 2009;299:161-176.
11. Allured VS, Collier RJ, Carroll SF, et al. Structure of exotoxin A of Pseudomonas aeruginosa at 3.0-Angstrom resolution. Proc Natl Acad Sci U S A. 1986;83:1320-1324.
12. Wedekind JE, Trame CB, Dorywalska M, et al. Refined crystallographic structure of Pseudomonas aeruginosa exotoxin A and its implications for the molecular mechanism of toxicity. J Mol Biol. 2001;314:823-837.
13. Horoszewicz JS, Leong SS, Chu TM, et al. The LNCaP cell line-a new model for studies on human prostatic carcinoma. Prog Clin Biol Res. 1980;37:115-132.
14. Wu HC, Hsieh JT, Gleave ME, et al. Derivation of androgenindependent human LNCaP prostatic cancer cell sublines: role of bone stromal cells. Int J Cancer. 1994;57:406-57:412.
15. Thalmann GN, Anezinis PE, Chang SM, et al. Androgenindependent cancer progression and bone metastasis in the LNCaP model of human prostate cancer. Cancer Res. 1994;54:2577-2581.
16. Sramkoski RM, Pretlow TG II, Giaconia JM, et al. A new human prostate carcinoma cell line, 22Rv1. In Vitro Cell Dev Biol Anim. 1999;35:403-409.
17. Elsasser-Beile U, Wolf P, Gierschner D, et al. A new generation of monoclonal and recombinant antibodies against celladherent prostate specific membrane antigen for diagnostic and therapeutic targeting of prostate cancer. Pr. Prrostate. 2006;66:1359-1370.
18. Kipriyanov SM, Moldenhauer G, Little M. High level production of soluble single chain antibodies in smallscale Escherichia coli cultures. J Immunol Methods. 1997;200:69-77.
19. Thalmann GN, Sikes RA, Wu TT, et al. LNCaP progression model of human prostate cancer: androgen-independence and osseous metastasis. Prostate. 2000;44:91-103 Jul. 101;144 (102).
20. Milenic DE, Yokota T, Filpula DR, et al. Construction, binding properties, metabolism, and tumor targeting of a single-chain Fv derived from the pancarcinoma monoclonal antibody CC49. Cancer Res. 1991;51:6363-6371.
21. Wolf P, Gierschner D, Buhler P, et al. A recombinant PSMAspecific single-chain immunotoxin has potent and selective toxicity against prostate cancer cells. Caancer Immunol Immunother. 2006;55:1367-1373.
22. Wolf P, Alt K, Buhler P, et al. Anti-PSMA immunotoxin as novel treatment for prostate cancer? High and specific antitumor activity on human prostate xenograft tumors in SCID mice. Prostate. 2008;68:129-138.
23. Singh R, Samant U, Hyland S, et al. Target-specific cytotoxic activity of recombinant immunotoxin scFv (MUC1)-ETA on breast carcinoma cells and primary breast tumors. Mol Cancer Ther. 2007;6:562-569.
24. Peipp M, Kupers H, Saul D, et al. A recombinant CD7-specific single-chain immunotoxin is a potent inducer of apoptosis in acute leukemic T cells. Caancer Res. 2002;62:2848-2855.
25. Barth S, Huhn M, Wels W, et al. Construction and in vitro evaluation of RFT5 (scFv)-ETA', a new recombinant singlechain immunotoxin with specific cytotoxicity toward CD25+ Hodgkin-derived cell lines. Int J Mol Med. 1998;1:249-256.
26. Klimka A, Barth S, Matthey B, et al. An anti-CD30 singlechain Fv selected by phage display and fused to Pseudomonas exotoxin A (Ki-4 (scFv)-ETA') is a potent immunotoxin against a Hodgkin-derived cell line. Br J Cancer. 1999;80:1214-1222.
27. Onda M, Olafsen T, Tsutsumi Y, et al. Cytotoxicity of antiosteosarcoma recombinant immunotoxins composed of TP-3 Fv fragments and a truncated Pseudomonas exotoxin A. J Immunother. 2001;24:144-150.
28. Onda M, Willingham M, Wang QC, et al. Inhibition of TNFalpha produced by Kupffer cells protects against the nonspecific liver toxicity of immunotoxin anti-Tac (Fv)-PE38, LMB-2. J Immunol. 2000;165:7150-7156.
29. Onda M, Kreitman RJ, Vasmatzis G, et al. Reduction of the nonspecific animal toxicity of anti-Tac (Fv)-PE38 by mutations in the framework regions of the Fv which lower the isoelectric point. J Immunol. 1999;163:6072-6077.
30. Onda M, Nagata S, Tsutsumi Y, et al. Lowering the isoelectric point of the Fv portion of recombinant immunotoxins leads to decreased nonspecific animal toxicity without affecting antitumor activity. Cancer Res. 2001;61:5070-5077.
31. Jung S, Pluckthun A. Improving in vivo folding and stability of a single-chain Fv antibody fragment by loop grafting. Protein Eng. 1997;10:959-966.
32. Worn A, Pluckthun A. Stability engineering of antibody singlechain Fv fragments. J Mol Biol. 2001;305:989-1010.
33. Onda M, Nagata S, FitzGerald DJ, et al. Characterization of the B cell epitopes associated with a truncated form of Pseudomonas exotoxin (PE38) used to make immunotoxins for the treatment of cancer patients. J Immunol. 2006;177:8822-8834.
34. Huang X, Bennett M, Thorpe PE. Anti-tumor effects and lack of side effects in mice of an immunotoxin directed against human and mouse prostate-specific membrane antigen. Prostate. 2004;61:1-11.
35. Russell PJ, Hewish D, Carter T, et al. Cytotoxic properties of immunoconjugates containing melittin-like peptide 101 against prostate cancer: in vitro and in vivo studies. Cancer Immunol Immunother. 2004;53:411-421.
36. Ma D, Hopf CE, Malewicz AD, et al. Potent antitumor activity of an auristatin-conjugated, fully human monoclonal antibody to prostate-specific membrane antigen. Clin Cancer Res. 2006;12:2591-2596.
37. Henry MD, Wen S, Silva MD, et al. A prostate-specific membrane antigen-targeted monoclonal antibody-chemotherapeutic conjugate designed for the treatment of prostate cancer. Caancer Res. 2004;64:7995-8001.
38. Galsky MD, Eisenberger M, Moore-Cooper S, et al. Phase I trial of the prostate-specific membrane antigen-directed immunoconjugate MLN2704 in patients with progressive metastatic castrationresistant prostate cancer. J Clin Oncol. 2008;26:2147-2154.
39. Elsasser-Beile U, Buhler P, Wolf P. Targeted therapies for prostate cancer against the prostate specific membrane antigen. Curr Drug Targets. 2009;10:118-125.
40. Lupold SE, Hicke BJ, Lin Y, et al. Identification and characterization of nuclease-stabilized RNA molecules that bind human prostate cancer cells via the prostate-specific membrane antigen. Cancer Res. 2002;62:4029-4033.
41. Chu TC, Marks JW III, Lavery LA, et al. Aptamer: toxin conjugates that specifically target prostate tumor cells. Cancer Res. 2006;66:5989-5992.
42. Dhar S, Gu FX, Langer R, et al. Targeted delivery of cisplatin to prostate cancer cells by aptamer functionalized Pt (IV) prodrug-PLGA-PEG nanoparticles. Proc Natl Acad Sci U S A. 2008;105:17356-17361.
43. Gong MC, Latouche JB, Krause A, et al. Cancer patient T cells genetically targeted to prostate-specific membrane antigen specifically lyse prostate cancer cells and release cytokines in response to prostate-specific membrane antigen. Neoplasia. 1999;1:123-127.
44. Gade TP, Hassen W, Santos E, et al. Targeted elimination of prostate cancer by genetically directed human T lymphocytes. Cancer Res. 2005;65:9080-9088.
45. Buhler P, Wolf P, Gierschner D, et al. A bispecific diabody directed against prostate-specific membrane antigen and CD3 induces T-cell mediated lysis of prostate cancer cells. Caancer Immunol Immunother. 2008;57:43-52.